Navigation Links
Scott & White Healthcare clinical trials target lymphoma, leukemia

Scott & White's Cancer Research Institute (CRI) is participating in an international study that targets adult relapsed or refractory B-cell Non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

"This study is important in our efforts to find new and better ways to treat patients with leukemia or lymphoma," said Arthur E. Frankel, M.D., director of Scott & White's Cancer Research Institute, and principal investigator for the Temple portion of the study. "Scott & White, as well as the entire Central Texas community, are fortunate to be included in this international research."

The Phase I/II study is open to eligible patients with previously treated B-cell non-Hodgkin's lymphoma (NHL), B-cell chronic lymphocytic leukemia (CLL), to include small lymphocytic lymphoma (SLL). B-cell lymphomas account for 80-90% of all Non-Hodgkin's Lymphomas. The clinical trial will evaluate the safety, tolerability, and efficacy of an investigative therapeutic research agent called CAT-8015.

This research will ultimately include 30 sites in the U.S., Canada and Europe and from 110 to 140 subjects. The study will last about 30 months.

"We want to determine if this agent is effective in destroying cancer cells using varying doses," said Dr. Frankel.


  • Chronic lymphocytic leukemia (CLL), more common in people age 60 and older, is a B-cell disorder in which white blood cells live longer than normal and accumulate in the blood and bone marrow and sometimes the lymph nodes. This accumulation of white blood cells crowds out healthy lymphocytes and causes immune system problems. About 15,490 new cases of CLL were diagnosed in 2009.
  • CLL and Small Lymphocytic Lymphoma (SLL) are the same disease with slight variations. When the cancer cells are primarily in the lymph nodes, it's called SLL.
  • Follicular Lymphoma, a slow-growing Lymphoma, accounts for 20-30% of the cases of Non-Hodgkin's Lymphoma. It occurs equally among males and female adults over the age of 60.
  • Diffuse Large B-Cell Lymphoma is an aggressive Non-Hodgkin's Lymphoma (NHL) that occurs in B-cells, and accounts for two out of five cases of NHL.
  • Mantle cell lymphoma (MCL) accounts for about 1 in 20 Non-Hodgkin's Lymphoma diagnoses in the United States; and typically occurs in patients over 30 years old, most frequently in males over the age of 50.


Contact: Katherine Voss
Scott & White Healthcare

Related medicine news :

1. Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages
2. New Varicose Vein Treatment Center Opens in Prescott, Arizona
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. Allergy Relief, Chiropractic and Biofeedback Provided at New Absolute Health Clinic in Scottsdale, Arizona
5. SUNZ Insurance Company Selects Scott Robertson as President
6. James Scott Farrin Supports Radiothon for Duke Children's Hospital
7. Scott & White Healthcare pathologist is co-investigator on breast cancer study
8. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
9. Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period
10. Scott Roeder Trial: Randall Terry, Operation Rescue Founder and Insurrecta Nex Members to Attend Trial in Wichita
11. New study shows TGen spin-off boosts Scottsdale economy
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: